| 引用本文: | 惠红岩,陈明,王学惠.硝酸酯类静脉剂型使用情况调查及合理性评价[J].中国现代应用药学,2016,33(3):339-342. |
| HUI Hongyan,CHEN Ming,WANG Xuehui.Investigation and Evaluation of Rationality of Nitrate Ester Intravenous Dosage Form Using Situation[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(3):339-342. |
|
| 摘要: |
| 目的 调查心血管内科使用硝酸酯类静脉剂型的情况并评价其合理性。方法 通过临床用药决策支持软件分别抽取2014年2~9月使用硝酸酯类静脉剂型的心血管内科病历；随机抽取符合条件的病历100份，根据《硝酸酯在心血管疾病中规范化应用的专家共识》及《硝酸酯类药物静脉应用建议》，对患者的适应证、静脉用药持续时间、是否与单硝酸异山梨酯缓释片联用等进行统计及合理性评价。结果 2014年2~9月，静脉单硝酸异山梨酯共计使用2 003例次；静脉硝酸异山梨酯共计使用45例次；静脉硝酸甘油共计使用1 092例次。随机抽取100份使用硝酸酯类静脉剂型的病历，79例使用单硝酸异山梨酯静脉剂型，药物选择不合理；3例使用硝酸异山梨酯静脉剂型和38例使用硝酸甘油静脉剂型，药物选择合理。82例与单硝酸异山梨酯缓释片联合使用，联合用药不合理。平均疗程分别为8.5 d和9.5 d，疗程偏长。结论 2014年2~9月，新乡医学院第一附属医院硝酸酯类静脉剂型选择品种不当；静脉剂型联合使用口服缓释剂型不合理；静脉用药疗程无依据，无评估。 |
| 关键词: 硝酸酯 静脉剂型 合理性 |
| DOI： |
| 分类号: |
| 基金项目:河南省科技发展计划项目(142300410191) |
|
| Investigation and Evaluation of Rationality of Nitrate Ester Intravenous Dosage Form Using Situation |
|
HUI Hongyan1, CHEN Ming1, WANG Xuehui2
|
|
1.The First Affiliated Hospital of Xinxiang Medical University, Department of Clinical Pharmacy, Xinxiang 453100, China;2.The First Affiliated Hospital of Xinxiang Medical University, Department of Cardiovascular, Xinxiang 453100, China
|
| Abstract: |
| OBJECTIVE To investigate cardiovascular internal medicine use of nitrate ester intravenous dosage form and to evaluate its rationality. METHODS Through the clinical medication decision support extraction from February 1, 2014 to September 30 patients with cardiovascular division was discharged. The medical records of 100 randomly selected in accordance with conditions, according to The Nitric Acid Ester Standardized Application in Cardiovascular Disease Expert Consensus and The Nitrate Drugs Intravenously Suggestions, indications, intravenous drug use, whether with isosorbide mononitrate zyban combination of statistics and the evaluation of the rationality. RESULTS From Feb to Sep in 2014, 5-ISMN-a total of 2 003 cases of vein, ISDN-a total of 45 cases, NTG-a total of 1 092 cases were incluede. A random sample of 100 using nitrates intravenous formulations of medical records, 82 cases combined utilization 5-ISMN sustained release tablet, combination is not reasonable. The average course of treatment were 8.5 d and 9.5 d. CONCLUSION From Feb to Sep in 2014, improper dosage form is selected of nitrate vein variety, intravenous formulations used in combination with oral sustained-release dosage form is not reasonable; intravenous medication treatment without the basis, without evaluation. |
| Key words: nitric acid ester intravenous formulations rationality |
